I will take that riddle... it’s because we all a
Post# of 148132
Dr BP let Nader know that Leronlimab isn’t limited to Just HIV. That Leronlimab has other future indication that might just work better for cancer immune oncology and some autoimmune diseases. For telling Nader these projected indications and the science behind the CCR5 method of action we learned a lot from Dr BP. When someone like Dr. BP has such a big impact on our future investment. You just fall in love with him.
Then Nader telling us investors that we will be pursuing these indication and choosing to trial these indications and open up the science of Leronlimab for the world to see. You can’t help but love them both. One for what he knew and the other for what he did in listening to the knowledge that was presented.
That’s my opinion and my answer to your riddle. The truth going forward is... we don’t need DR BP anymore and Dr. BP doesn’t need Cytodyn. We have both progressed past our relationship and have no need to revisit again. But that relationship will always be one that us... as investors will live to remember and will cherish because of what we will accomplish in the future. It will always be a fond memory. There is always a time to move forward that makes sense. We have now made that move forward and we have our own journey to complete as does Dr. BP.. It is where we are at currently and the sooner everyone accepts this the sooner we will all see the future impact of what we are a part of and just how important the science is behind our miracle molecule.